Galcanezumab对偏头痛患者功能与失能影响的随机研究
两项随机对照试验(EVOLVE-1和EVOLVE-2)评估Galcanezumab对比安慰剂对发作性偏头痛患者报告的功能和失能结局的影响。患者接受Galcanezumab 120mg或240mg或安慰剂治疗6个月,MSQv2.1和MIDAS评估显示Galcanezumab在改善功能和减少失能方面显著优于安慰剂。
要点
- Galcanezumab 120mg和240mg在改善MSQv2.1总分上均显著优于安慰剂(p<0.001)。
- Galcanezumab在减少MIDAS评分上显著优于安慰剂,EVOLVE-1中120mg和240mg分别差-6.3和-5.2。
- 功能改善最早在治疗第1个月出现,并在6个月内大部分维度持续。
核心结论
- Galcanezumab治疗发作性偏头痛患者可显著改善日常功能并减少失能,效果优于安慰剂。
研究设计与样本
- 两项随机对照试验EVOLVE-1和EVOLVE-2,纳入发作性偏头痛患者(每月4-14天偏头痛日)。
- 患者接受Galcanezumab 120mg或240mg或安慰剂治疗6个月,评估MSQv2.1和MIDAS。
主要发现
- MSQv2.1总分变化(第4-6月)Galcanezumab 120mg和240mg vs 安慰剂:EVOLVE-1差值7.3和6.7(均p<0.001),EVOLVE-2差值8.5和7.3(均p<0.001)。
- 所有MSQv2.1维度评分Galcanezumab均显著优于安慰剂(p<0.001)。
- MIDAS评分变化(第6月)Galcanezumab 120mg和240mg vs 安慰剂:EVOLVE-1差值-6.3(p<0.001)和-5.2(p=0.002);EVOLVE-2差值-9.2和-8.2(均p<0.001)。
关键数值与推荐
- MSQv2.1总分改善在治疗第1个月即可观察到,并在6个月内大部分维度持续。
- MIDAS评估仅在治疗第3和第6个月收集。
临床怎么用
- 对于发作性偏头痛患者,Galcanezumab 120mg或240mg每月一次可改善患者报告的功能并减少失能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo. METHODS: Patients with episodic migraine (4-14 monthly migraine headache days) were treated with either galcanezumab (Evaluation of LY2951742 in the Prevention of Episodic Migraine [EVOLVE]-1: 120 mg n = 210, 240 mg n = 208; EVOLVE-2: 120 mg n = 226, 240 mg n = 220) or placebo (EVOLVE-1 n = 425; EVOLVE-2 n = 450) during 6 months of treatment. Migraine-Specific Quality of Life Questionnaire v2.1 (MSQv2.1) measured the effect of migraine on patient functioning (physical and emotional) in 3 domains, and the Migraine Disability Assessment (MIDAS) quantified headache-related disability associated with missed or reduced productivity at work or home and social events. Both were collected at baseline and during the treatment period (MSQv2.1 = monthly; MIDAS = months 3 and 6 only). RESULTS: Differences in MSQv2.1 total score least squares (LS) mean change from baseline (month 4-6) for galcanezumab (120 and 240 mg, respectively) were superior to placebo (EVOLVE-1 = 7.3 and 6.7 [both p < 0.001]; EVOLVE-2 = 8.5 and 7.3 [both p < 0.001]). Differences were similar for all domain scores (p < 0.001 for both galcanezumab doses compared with placebo), were observed as early as month 1, and were sustained for 6 months for most domains. Differences of MIDAS LS mean change from baseline (month 6) for galcanezumab (120 and 240 mg, respectively) compared with placebo were: EVOLVE-1 = -6.3 (p < 0.001) and -5.2 (p = 0.002); EVOLVE-2 = -9.2 and -8.2 (both p < 0.001). CONCLUSIONS: Patients with episodic migraine treated with galcanezumab reported significant and clinically meaningful improvements in daily functioning and decreased disability compared with patients who received placebo. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, galcanezumab (120 mg or 240 mg) given once monthly improved functioning and reduced disability.
引用
- Ford JH, Ayer DW, Zhang Q, et al. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability. Neurology. 2019. PMID: 31270220. doi:10.1212/WNL.0000000000007856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。